Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS MORIARITY

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1669443065
CMS profile
74954
Location
SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,303.22

147 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,303.22 147

By paying entity

PY2020 · entire year · sorted by reported total

Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS MORIARITY

NPI 1669443065 · CMS profile ID 74954

Allopathic & Osteopathic Physicians / Internal Medicine

SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669443065?year=2020&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS MORIARITY, NPI 1669443065, CMS profile ID 74954. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669443065?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). THOMAS MORIARITY, NPI 1669443065, CMS profile ID 74954. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669443065?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
THOMAS MORIARITY, NPI 1669443065, CMS profile ID 74954, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–147 of 147 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1669443065?year=2020&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

147 matching records · $1,303.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 147 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–147 of 147.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Supernus Pharmaceuticals, Inc. $6.7204/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351169 CMS
Harmony Biosciences LLC $18.4604/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750469017 CMS
Supernus Pharmaceuticals, Inc. $4.4404/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351167 CMS
AstraZeneca Pharmaceuticals LP $11.5004/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738703475 CMS
AstraZeneca Pharmaceuticals LP $17.0504/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738686085 CMS
Supernus Pharmaceuticals, Inc. $4.2304/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351165 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.8304/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721009125 CMS
Supernus Pharmaceuticals, Inc. $5.1703/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351163 CMS
Supernus Pharmaceuticals, Inc. $2.1903/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351161 CMS
Supernus Pharmaceuticals, Inc. $6.3503/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351159 CMS
Supernus Pharmaceuticals, Inc. $1.8603/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351157 CMS
Amgen Inc. $6.9403/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741334249 CMS
AstraZeneca Pharmaceuticals LP $13.5403/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738674427 CMS
Supernus Pharmaceuticals, Inc. $1.8603/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351155 CMS
Supernus Pharmaceuticals, Inc. $2.1802/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351153 CMS
AstraZeneca Pharmaceuticals LP $22.5302/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738698413 CMS
Supernus Pharmaceuticals, Inc. $1.8602/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351151 CMS
Amgen Inc. $4.8702/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741334241 CMS
Novartis Pharmaceuticals Corporation $13.6002/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726032669 CMS
Novo Nordisk Inc $12.5702/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744607535 CMS
SANOFI-AVENTIS U.S. LLC $16.0402/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744181841 CMS
Novo Nordisk Inc $17.1202/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744630249 CMS
Supernus Pharmaceuticals, Inc. $3.4602/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351149 CMS
AstraZeneca Pharmaceuticals LP $15.9802/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738671291 CMS
Janssen Pharmaceuticals, Inc $16.8602/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719455537 CMS
Supernus Pharmaceuticals, Inc. $2.3602/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351147 CMS
Supernus Pharmaceuticals, Inc. $2.5502/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351145 CMS
Supernus Pharmaceuticals, Inc. $2.4901/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351143 CMS
Supernus Pharmaceuticals, Inc. $13.1801/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351141 CMS
Kowa Pharmaceuticals America, Inc. $12.2701/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716757065 CMS
Supernus Pharmaceuticals, Inc. $4.2301/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351135 CMS
Supernus Pharmaceuticals, Inc. $1.9901/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351137 CMS
Supernus Pharmaceuticals, Inc. $9.1501/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351133 CMS
AstraZeneca Pharmaceuticals LP $14.9301/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738708439 CMS
Supernus Pharmaceuticals, Inc. $3.7101/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351131 CMS
Supernus Pharmaceuticals, Inc. $2.0201/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351129 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.9801/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747269873 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.3701/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747269871 CMS
Supernus Pharmaceuticals, Inc. $2.1201/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351127 CMS
Teva Pharmaceuticals USA, Inc. $11.5701/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749448003 CMS
AstraZeneca Pharmaceuticals LP $11.7401/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738704547 CMS
Supernus Pharmaceuticals, Inc. $2.1101/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351125 CMS
Amgen Inc. $4.4101/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741334239 CMS
Arbor Pharmaceuticals, Inc. $12.8401/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735736759 CMS
Supernus Pharmaceuticals, Inc. $1.8801/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351123 CMS
Supernus Pharmaceuticals, Inc. $1.8601/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748351121 CMS
Amgen Inc. $6.9401/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741334247 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,521.90 146
PY2020 $1,303.22 147
PY2021 $1,841.06 132
PY2022 $1,648.79 98
PY2023 $4,201.75 124
PY2024 $3,567.25 75
PY2025 $1,578.50 81

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $930,659.17 220
PY2024 Principal investigator $1,529,192.32 69
PY2023 Principal investigator $1,162,738.34 75
PY2022 Principal investigator $634,676.57 43
PY2021 Principal investigator $324,005.13 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

220 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $17,869.50 12/19/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978980
Principal investigator 1 ModernaTX, Inc. $1,588.40 12/19/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979046
Principal investigator 1 PFIZER INC. $351.00 12/19/2025 Non-covered Recipient Entity
Javara Privia Medical Group
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228805937
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 12/17/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631851
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 12/17/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631853
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 12/17/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631881
Principal investigator 1 PFIZER INC. $1,140.62 12/17/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228816255
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,644.00 12/15/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801852
Principal investigator 1 Alnylam Pharmaceuticals Inc. $400.00 12/12/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518858
Principal investigator 1 PFIZER INC. $4,363.19 12/12/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228815938
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,000.00 12/09/2025 Non-covered Recipient Entity
Javara Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220801886
Principal investigator 1 PFIZER INC. $1,140.62 12/09/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228816428
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 12/05/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220994561
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,279.13 12/02/2025 Non-covered Recipient Entity
FELLOWS RESEARCH ALLIANCE INC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190299568
Principal investigator 1 Alnylam Pharmaceuticals Inc. $346.95 12/01/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,040.85 12/01/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518875
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631839
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631841
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631843
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631845
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631847
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631849
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631875
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/26/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220994559
Principal investigator 1 PFIZER INC. $128.00 11/26/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228713992
Principal investigator 1 Alnylam Pharmaceuticals Inc. $130.00 11/19/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518867
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 11/19/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631879
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,701.00 11/13/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801850
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 11/07/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220792707
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631827
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631829
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631831
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631833
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631835
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631837
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631873
Principal investigator 1 PFIZER INC. $10,505.99 10/31/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228825589
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 10/27/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631877
Principal investigator 1 PFIZER INC. $50,570.53 10/25/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228825147
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 10/21/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220994555
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 10/17/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220994557
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,900.00 10/08/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518862
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,462.35 10/03/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801848
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631815
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631817
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631819
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631821
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631823
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631825
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631871
Principal investigator 1 ModernaTX, Inc. $1,692.90 09/29/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978976
Principal investigator 1 ModernaTX, Inc. $1,391.75 09/29/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979000
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 09/24/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631811
Principal investigator 1 Boehringer Ingelheim International GmbH $19.14 09/24/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631813
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,313.00 09/22/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801846
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,200.00 09/22/2025 Non-covered Recipient Entity
Javara Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220801884
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 09/11/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220994553
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631783
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631785
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631787
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631789
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631791
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631809
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631865
Principal investigator 1 Cleerly, Inc. $26,348.00 08/31/2025 Non-covered Recipient Entity
Cumberland County Hospital System, Inc., d/b/a Cape Fear Valley Health System (Javara Inc.)
TRANSFORM No dispute reported 06/30/2026 1241148419
Principal investigator 1 ModernaTX, Inc. $3,061.85 08/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978972
Principal investigator 1 ModernaTX, Inc. $1,651.10 08/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979002
Principal investigator 1 ModernaTX, Inc. $5,956.50 08/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979004
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $256.00 08/27/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801844
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631867
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631869
Principal investigator 1 PFIZER INC. $1,502.45 08/21/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228828244
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 08/18/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220792709
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,314.00 08/14/2025 Non-covered Recipient Entity
FELLOWS RESEARCH ALLIANCE INC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190299572
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34,273.00 08/06/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801842
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631773
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631775
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631777
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631779
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631781
Principal investigator 1 Boehringer Ingelheim International GmbH $46.18 08/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631803
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631807
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631863
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $640.00 07/30/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801840
Principal investigator 1 ModernaTX, Inc. $459.80 07/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978984
Principal investigator 1 ModernaTX, Inc. $2,978.25 07/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978996
Principal investigator 1 ModernaTX, Inc. $278.35 07/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979018
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,420.00 07/19/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801838
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,139.25 07/16/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518705
Principal investigator 1 PFIZER INC. $5,415.40 07/11/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228830687
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,389.00 07/09/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801834
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,157.00 07/09/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801836
Principal investigator 1 PFIZER INC. $283.13 07/07/2025 Non-covered Recipient Entity
Javara Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228713802
Principal investigator 1 PFIZER INC. $331.89 07/07/2025 Non-covered Recipient Entity
Javara Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228713804
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631793
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631795
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631797
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631799
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631801
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631805
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 07/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631855
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 07/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631857
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631859
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 07/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220631861
Principal investigator 1 ModernaTX, Inc. $5,956.50 06/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978998
Principal investigator 1 ModernaTX, Inc. $1,672.00 06/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979012
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,537.00 06/26/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801832
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631771
Principal investigator 1 ModernaTX, Inc. $18,862.25 06/18/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978974
Principal investigator 1 ModernaTX, Inc. $2,048.20 06/18/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978988
Principal investigator 1 ModernaTX, Inc. $4,175.25 06/18/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979022
Principal investigator 1 Alnylam Pharmaceuticals Inc. $423.00 06/04/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518671
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631751
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631753
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631755
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631757
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631759
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631761
Principal investigator 1 ModernaTX, Inc. $28,661.50 05/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978986
Principal investigator 1 ModernaTX, Inc. $12,804.10 05/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979006
Principal investigator 1 ModernaTX, Inc. $5,956.50 05/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979020
Principal investigator 1 ModernaTX, Inc. $2,403.50 05/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979026
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 05/27/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631765
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 05/27/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631767
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 05/27/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631769
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $884.00 05/27/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801826
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $931.00 05/27/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801828
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,502.00 05/27/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801830
Principal investigator 1 ModernaTX, Inc. $2,000.00 05/23/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978968
Principal investigator 1 Alnylam Pharmaceuticals Inc. $321.30 05/14/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518675
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,208.00 05/09/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801824
Principal investigator 1 AstraZeneca UK Limited $10,899.42 05/07/2025 Non-covered Recipient Entity
JAVARA, INC
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185541686
Principal investigator 1 ModernaTX, Inc. $1,885.82 05/07/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979044
Principal investigator 1 PFIZER INC. $1,974.52 05/07/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228831941
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631739
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631741
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631743
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631745
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631747
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631749
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,840.00 05/01/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801814
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,157.00 05/01/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801816
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,002.00 05/01/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801818
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $574.00 05/01/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801820
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,314.00 05/01/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801822
Principal investigator 1 ModernaTX, Inc. $1,379.40 04/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978994
Principal investigator 1 ModernaTX, Inc. $438.90 04/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979016
Principal investigator 1 ModernaTX, Inc. $3,896.90 04/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979024
Principal investigator 1 ModernaTX, Inc. $950.00 04/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979034
Principal investigator 1 ModernaTX, Inc. $7,237.10 04/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979036
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 04/23/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631763
Principal investigator 1 PFIZER INC. $649.76 04/17/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228831925
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,916.00 04/11/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801812
Principal investigator 1 PFIZER INC. $2,765.62 04/11/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228831933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,426.50 04/01/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518687
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631725
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631727
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631729
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631731
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631733
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631735
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $48,884.00 03/24/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801810
Principal investigator 1 ModernaTX, Inc. $1,588.40 03/24/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979010
Principal investigator 1 ModernaTX, Inc. $6,680.40 03/24/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979040
Principal investigator 1 ModernaTX, Inc. $5,956.50 03/24/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979042
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,579.26 03/12/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518544
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,637.03 03/12/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518598
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $875.00 03/12/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801808
Principal investigator 1 PFIZER INC. $4,548.32 03/12/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228833288
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,342.22 03/10/2025 Non-covered Recipient Entity
FELLOWS RESEARCH ALLIANCE INC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190299576
Principal investigator 1 PFIZER INC. $5,847.84 03/05/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228833682
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631705
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631707
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631709
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631711
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631713
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631715
Principal investigator 1 ModernaTX, Inc. $11,464.60 02/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978966
Principal investigator 1 ModernaTX, Inc. $1,504.80 02/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978970
Principal investigator 1 ModernaTX, Inc. $9,463.90 02/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978990
Principal investigator 1 ModernaTX, Inc. $12,905.75 02/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979028
Principal investigator 1 ModernaTX, Inc. $1,860.10 02/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979030
Principal investigator 1 PFIZER INC. $649.76 02/26/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228826284
Principal investigator 1 Alnylam Pharmaceuticals Inc. $175.50 02/21/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518532
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,045.30 02/21/2025 Non-covered Recipient Entity
Javara Inc
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518553
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,108.00 02/13/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801806
Principal investigator 1 PFIZER INC. $757.35 02/12/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228826254
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631693
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631695
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631697
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631699
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631701
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631703
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,614.00 01/30/2025 Non-covered Recipient Entity
JAVARA, INC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190310683
Principal investigator 1 ModernaTX, Inc. $5,956.50 01/29/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978978
Principal investigator 1 ModernaTX, Inc. $543.40 01/29/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978982
Principal investigator 1 ModernaTX, Inc. $348.65 01/29/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252978992
Principal investigator 1 ModernaTX, Inc. $752.40 01/29/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979008
Principal investigator 1 ModernaTX, Inc. $5,567.00 01/29/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979014
Principal investigator 1 ModernaTX, Inc. $5,732.30 01/29/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979032
Principal investigator 1 ModernaTX, Inc. $4,693.00 01/29/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252979038
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $574.00 01/28/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801802
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,315.00 01/28/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801804
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 01/27/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631717
Principal investigator 1 Boehringer Ingelheim International GmbH $279.72 01/27/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631719
Principal investigator 1 Boehringer Ingelheim International GmbH $38.64 01/27/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631721
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,958.00 01/27/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801796
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,148.00 01/27/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801798
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27,830.00 01/27/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801800
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $109,560.52 01/27/2025 Non-covered Recipient Entity
JAVARA INC.PRIVIA MEDICAL GROUP SAVANNAH GA
A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease No dispute reported 06/30/2026 1214124354
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,044.00 01/17/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801792
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,533.00 01/13/2025 Non-covered Recipient Entity
Javara Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801794
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631683
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631685
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631687
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631689
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631691
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631723
Principal investigator 1 Boehringer Ingelheim International GmbH $15.39 01/01/2025 Non-covered Recipient Entity
Southcoast Health Savannah Campus Building 1
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220631737
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $105,301.76 01/01/2025 Non-covered Recipient Entity
JAVARA INC.PRIVIA MEDICAL GROUP SAVANNAH GA
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1214124062